Compositions and methods for improving heart function
View Patent ↗The present invention relates to treating or ameliorating heart disease associated with poor myocardial performance, e.g., diabetic cardiomyopathy and associated disorders, particularly to treating, preventing or ameliorating such disorders through inhibition of O-GlcNAcylation and/or increased activity of O-GlnNAcase. The invention provides vectors for gene transfer of O-GlnNAcase. In one aspect, the invention provides cells, vectors, formulations comprising them and methods of using them, for the gene transfer of the human O-GlnNAcase gene, e.g., to treat conditions and diseases associated with impaired cardiac contractility, such as that, found associated with diabetic cardiomyopathy. In another aspect, the invention provides non-human transgenic animals and host cells comprising genetically engineered cells having increased activity of O-GlnNAcase.
1. A method for normalizing or improving calcium cycling in a myocyte under hyperglycemic or diabetic conditions, or a diabetic heart, by enhancing the Ca 2+ transient and sarcoplasmic reticulum Ca 2+ loading, the method comprising increasing O-GlcNAcase (GCA) enzyme levels and activity in the myocyte by
(a) providing a nucleic acid encoding an O-GlcNAcase (GCA) enzyme, wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart; and
(b) directly administering an effective amount of the O-GlcNAcase (GCA)-encoding nucleic acid to the myocyte or heart, and inducing expression of the O-GlcNAcase-encoding nucleic acid if the promoter is an inducible promoter, thereby expressing an O-GlcNAcase (GCA) enzyme in the myocyte to reduce excess O-GlcNAcylation and enhance Ca 2+ transient and sarcoplasmic reticulum Ca 2+ loading in the myocyte or the diabetic heart.
2. The method of claim 1 , wherein an effective amount of the O-GlcNAcase (GCA)-encoding nucleic acid is administered to the diabetic myocyte ex vivo.
3. The method of claim 1 , wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes.
4. The method of claim 1 , wherein administering the effective amount of the GCA-encoding nucleic acid causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins.
5. The method of claim 1 , wherein a GCA-encoding nucleic acid is contained within a cloning vehicle, an expression cassette or vector.
6. The method of claim 5 , wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome.
7. The method of claim 1 , wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector.
8. The method of claim 7 , wherein the retroviral vector is a lentiviral vector.
9. An in vitro method for normalizing or improving calcium cycling in a myocyte under hyperglycemic or diabetic conditions, the method comprising increasing O-GlcNAcase (GCA) enzyme levels and activity in the myocyte by:
(a) providing a nucleic acid encoding an O-GlcNAcase (GCA) enzyme, wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte; and
(b) directly administering an effective amount of the O-GlcNAcase (GCA)-encoding nucleic acid to the myocyte, and inducing expression of the O-GlcNAcase -encoding nucleic acid if the promoter is an inducible promoter, thereby expressing an O-GlcNAcase (GCA) enzyme in the myocyte to reduce excess O-GlcNAcylation and enhance Ca 2+ transient and sarcoplasmic reticulum Ca 2+ loading in the myocyte.
10. The method of claim 1 , wherein an effective amount of the O-GlcNAcase (GCA)-encoding nucleic acid is administered to the heart ex vivo.